CompanyOverview|NASDAQ:RXRX] Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to ...

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

On December 17, 2025, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from Neutral to Overweight, with a price ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

Shares of clinical stage biotech company Recursion Pharmaceuticals Inc RXRX are trading higher Tuesday. The company’s CEO Chris Gibson joined CNBC for an interview ahead of a presentation with Nvidia ...

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

The financial health of Recursion is further illuminated by its revenue figures. InvestingPro data shows that the company's revenue for the last twelve months as of Q2 2024 was $49.63 million.

The Gateway in Salt Lake City took a major leap this week in its evolution into something more than a retail center, with the addition of Recursion Pharmaceuticals as a core tenant. The 5-year-old ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...